Wire · regulatory
Montana is trying to break the FDA's monopoly on experimental treatments
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Montana has passed a law allowing patients with any condition to access experimental therapies that have cleared Phase 1 clinical trials, bypassing the FDA approval process and permitting companies to charge market prices. The program faces potential federal enforcement risks but aims to lower treatment costs and increase patient access.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Sep 2026 and 18 Sep 2026.
◆ ◆ The Wire takeaway
Montana's law challenges the FDA's control over experimental treatments by letting companies charge for therapies beyond life-threatening conditions. If you develop early-stage biotech drugs, this could open a new, faster route to market within the state but expect legal pushback that could affect operational stability.
◆ Coverage
2 sources · first reported 16 Sep 2026 · latest 18 Sep 2026
◆ Related on Wire
◆ Topics